Nuvalore Enhances Drug Development Efficiency with Fast, Robust Analytical Method Development, Validation & Transfer Services

nuvalore is strengthening its position as a trusted analytical partner for biopharmaceutical companies, emphasizing the depth, speed, and regulatory strength of its core analytical method development, validation, and transfer services. These capabilities help development teams accelerate timelines, maintain compliance, and avoid the analytical setbacks that frequently disrupt drug programs.

Analytical methods are a critical control point in pharmaceutical development, yet many programs face delays caused by inconsistent performance and incomplete method understanding. nuvalore mitigates these risks through a QbD/AQbD-aligned, lifecycle-driven approach that strengthens method performance from early development through commercialization.

“Our clients work under tight, high-stakes timelines,” said Dr. Anamarija Curic, Founder and CEO of nuvalore. “They need analytical methods that not only pass validation, but continue performing reliably across labs, instruments, and phases of development. We pair deep scientific rigor with rapid onboarding so teams can keep moving without interruption.”

Lifecycle-driven analytical design that Reduces Risk at Every Stage

nuvalore develops methods with long-term performance in mind, defining clear objectives and building strong control strategies that support scale-up, tech transfer, and post-approval changes. This enhances IND/NDA readiness and reduces risk at every stage.

Fast Project Initiation and Predictable Timelines

Streamlined intake, direct scientist communication, and efficient planning allow nuvalore to begin work quickly — helping teams progress without delay.

Robust Scientific Foundation

Every method is designed with clear performance targets, data-driven robustness assessments, and modern QbD tools such as DoE and parameter mapping to ensure durability in real QC environments.

GMP-ready Validation & Regulatory Alignment

Nuvalore’s validation protocols incorporate clear acceptance criteria, rigorous statistical justification, and full alignment with ICH Q2(R2), Q14, and GMP expectations to ensure methods perform reliably in real QC environments.

Low-risk Method Transfers

Comprehensive transfer packages provide receiving labs with critical parameters, allowable variability, and practical guidance that minimizes investigations and rework.

Broad modality coverage

nuvalore brings deep industry knowledge and supports small molecules, biologics, peptides, biosimilars, and complex modalities.

Companies partnering with nuvalore see measurable advantages: fewer analytical failures, faster batch release, reduced back-and-forth during tech transfers, and stronger regulatory submissions. By eliminating variability early and building methods to withstand operational realities, nuvalore helps teams maintain development velocity without compromising quality.

More information on nuvalore’s Analytical Method Development, Validation & Transfer services is available at:

https://nuvalore.com/en/analytical-method-development-validation-transfer/